Realcan Pharmaceutical Group Co., Ltd. (SHE:002589)
China · Delayed Price · Currency is CNY 2.920
-0.020 (-0.68%)
Jun 2, 2026, 3:04 PM CST
SHE:002589 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | 14.35 | 16.07 | 12.29 | 20.32 | -1,831 | 131.18 |
Depreciation & Amortization | 151.59 | 151.59 | 199.28 | 219.68 | 283.88 | 319.22 |
Other Amortization | 44.24 | 44.24 | 16.91 | 25.75 | 32.88 | 44.42 |
Loss (Gain) From Sale of Assets | -1.82 | -1.82 | -18.94 | 7.92 | 1 | -3.06 |
Asset Writedown & Restructuring Costs | 0.71 | 0.71 | 0.61 | 4.91 | 47.83 | 39.9 |
Loss (Gain) From Sale of Investments | -90.6 | -90.6 | -114.4 | -424.59 | 656.44 | -103.46 |
Provision & Write-off of Bad Debts | -13.32 | -13.32 | 43.12 | 10.01 | 159.22 | 158.77 |
Other Operating Activities | 216.36 | 255.41 | 225.9 | 651.21 | 1,036 | 822.64 |
Change in Accounts Receivable | 439.06 | 439.06 | 59.63 | 1,122 | -6,340 | -197.21 |
Change in Inventory | 15.8 | 15.8 | 385.04 | -165.26 | 190.72 | 476.9 |
Change in Accounts Payable | -763.02 | -763.02 | -647.97 | -1,219 | 6,314 | -1,069 |
Operating Cash Flow | -27 | 13.76 | 160.79 | 82.47 | 523.07 | 442.95 |
Operating Cash Flow Growth | - | -91.44% | 94.98% | -84.23% | 18.09% | 6.75% |
Capital Expenditures | -13.57 | -26.82 | -111.57 | -298.38 | -170.96 | -461.09 |
Sale of Property, Plant & Equipment | -5.77 | 0.53 | 0.75 | 0.71 | 83.97 | 13.35 |
Cash Acquisitions | - | - | - | - | -70.37 | -173.27 |
Divestitures | 82.75 | 81.47 | 224.06 | 1,163 | 982.53 | 82.08 |
Investment in Securities | -220 | -120 | 90.5 | -285.98 | -297.63 | -80.58 |
Other Investing Activities | 10.28 | 13.02 | 0.2 | 0.3 | 32.77 | 20.44 |
Investing Cash Flow | -146.31 | -51.8 | 203.93 | 579.53 | 592.96 | -583.51 |
Short-Term Debt Issued | - | 6,134 | 8,044 | 20,785 | 6,271 | 8,480 |
Long-Term Debt Issued | - | 3,361 | 2,809 | 5,406 | 11,159 | 11,066 |
Total Debt Issued | 9,431 | 9,495 | 10,853 | 26,191 | 17,430 | 19,547 |
Short-Term Debt Repaid | - | -7,173 | -6,858 | -22,609 | -14,030 | -12,372 |
Long-Term Debt Repaid | - | -3,680 | -2,968 | -3,975 | -4,347 | -6,824 |
Total Debt Repaid | -10,024 | -10,853 | -9,826 | -26,584 | -18,377 | -19,196 |
Net Debt Issued (Repaid) | -593.15 | -1,358 | 1,027 | -393.11 | -947.42 | 350.84 |
Issuance of Common Stock | 20 | 20 | 78.61 | 26.3 | 68.7 | 4.24 |
Repurchase of Common Stock | -101.48 | -101.48 | -33.34 | -28.54 | -29.58 | -4.4 |
Common Dividends Paid | -178.77 | -174.5 | -198.92 | -201.69 | -154.31 | -316.31 |
Other Financing Activities | 972.54 | 1,680 | -1,020 | -80.15 | -402.52 | -84.78 |
Financing Cash Flow | 119.14 | 65.96 | -146.69 | -677.2 | -1,465 | -50.42 |
Foreign Exchange Rate Adjustments | - | - | - | -0 | 0 | -0 |
Net Cash Flow | -54.17 | 27.92 | 218.04 | -15.2 | -349.09 | -190.98 |
Free Cash Flow | -40.57 | -13.06 | 49.22 | -215.92 | 352.11 | -18.13 |
Free Cash Flow Margin | -0.56% | -0.18% | 0.62% | -2.69% | 2.86% | -0.09% |
Free Cash Flow Per Share | -0.03 | -0.01 | 0.04 | -0.14 | 0.24 | -0.01 |
Cash Interest Paid | 7.37 | 7.37 | 20.69 | 19.57 | 36.58 | 43.35 |
Cash Income Tax Paid | 137.84 | 135.46 | 165.97 | 135.3 | 398.68 | 928.46 |
Levered Free Cash Flow | 2,319 | 1,095 | -109.7 | -3,610 | 4,920 | 5,678 |
Unlevered Free Cash Flow | 2,418 | 1,207 | 11.6 | -3,421 | 5,175 | 6,024 |
Change in Working Capital | -348.53 | -348.53 | -203.98 | -432.75 | 136.28 | -966.67 |